Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib
ABSTRACT 06/2020
For more information about this publication, please submit a medical information request.
Aspen: Results of a phase 3 randomized trial of Zanubrutinib vs. Ibrutinib for patients with Waldenström macroglobulinemia